About this trial
What are the requirements for participating in this study?
1. Age 40 to 69, gender unlimited; 2. Insomnia symptoms (difficulty falling asleep, frequent awakenings during sleep, early morning awakening, etc.) occurring three or more times per week for three months or longer (meeting DSM-5 diagnostic criteria for chronic insomnia and International Classification of Sleep Disorders standards); 3.7 points \<ISI baseline score ≤ 21 points (mild to moderate insomnia);
4\. The patient is dissatisfied (option 3) or very dissatisfied (option 4) with their current sleep 5. The incubation period or wake time after falling asleep is more than 30 minutes, and the total sleep time is less than 6.5 hours per day; 6. Willing to follow the exercise prescription and coach's guidance, and cooperate with the exercise intervention for 6 weeks; 7. Being able to maintain consistent lifestyle and sleep patterns throughout the study; 8. Fixed residence and no expectation of moving or traveling within 6 weeks; 9. Sign the informed consent form.
You are not eligible to participate in this study if you meet any of the following criteria:
1. Exclude diseases that affect sleep (such as tumors, dementia, obstructive sleep apnea, etc.); 2. Taking medications that may affect sleep (such as steroid hormones, sleeping pills, psychotropic drugs); 3. Abuse of alcohol or drugs in the last 3 months; 4. Liver or kidney dysfunction; 5. History of severe cardiovascular and cerebrovascular diseases; 6. History of mental illness; 7. Expect to work night shifts or travel across time zones or sleep irregularly during the study period; 8. Participated in other intervention clinical trials, including drugs, nutritional preparations and medical devices, within 3 months before the study.
What will I experience if I participate in this study? If eligible, participants will be randomly assigned by physicians to one of two study phases: the screening and baseline assessment phase, or the intervention and follow-up phase. The trial consists of three phases, each containing two phases (experimental or control, lasting 1-2 weeks). After enrollment, participants will be randomly assigned to either the Tai Chi intervention group or the walking control group. Throughout the study, participants must cooperate with physicians to complete relevant questionnaires and attend scheduled follow-up visits.
What might be the benefits of participating in this study? The research team will cover all expenses for the exercise program. Participants will receive free exercise training, physiological counseling, and standardized assessments throughout the study, including follow-up sessions. Our previous sports medicine research shows that 12 weeks of Tai Chi therapy can significantly improve insomnia symptoms.
What are the risks of participating in this study? Participants who have not exercised for a long time may have adverse reactions such as muscle pain and joint pain caused by exercise in the early stage of the experiment or during the study, or even lead to the termination of the experiment.
Is participation in this study mandatory? No, participation in this study is entirely voluntary.
Can I quit the study midway? Yes, you can opt out at any time, and this will not affect your legal right to continue regular checkups or treatments.
Are my personal information confidential? Your personal privacy will be strictly protected within the bounds of applicable laws. Monitoring officers, auditors, ethics committees, and management authorities shall be permitted to directly access participants 'original medical records to verify clinical trial procedures and data, provided such access does not violate applicable laws and regulations or infringe upon participants' privacy. Throughout the study, participants have the right to withdraw from the research at any time without facing discrimination, retaliation, or disruption of medical services. All personal information collected during the study remains confidential. Participants are entitled to consult our physicians with any questions at any time.
Patient Statement (Please tick in parentheses):
1. I have reviewed the relevant research materials for this study (version v1.0)···········□ 2. I have carefully considered the matter, consulted a doctor about the relevant issues, and received satisfactory answers······□ 3. I understand that participation in this study is voluntary and that I have the right to withdraw from this study at any time without any reason without affecting my medical treatment and rights·····□ 4. I understand that my relevant materials will be reviewed by the research unit or members of the strict management agency in this study. I agree to the above personnel reviewing and using my relevant materials. ·······················□ 5. I agree to participate in this study·····························□
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age 40 to 69, gender unlimited;
Insomnia symptoms (difficulty falling asleep, frequent awakenings during sleep, early morning awakening, etc.) occurring three or more times per week for three months or longer (meeting DSM-5 diagnostic criteria for chronic insomnia and International Classification of Sleep Disorders standards); 3.7 points <ISI baseline score ≤ 21 points (mild to moderate insomnia);
Disqualifiers
Exclude diseases that affect sleep (such as tumors, dementia, obstructive sleep apnea, etc.);
Taking medications that may affect sleep (such as steroid hormones, sleeping pills, psychotropic drugs);
Abuse of alcohol or drugs in the last 3 months;
Liver or kidney dysfunction;
Trial population
he study population consists of individuals aged 40 to 69 years diagnosed with insomnia, defined according to the diagnostic criteria of the International Classification of Sleep Disorders (ICSD-3) or the Diagnostic and Statistical Manual of Mental Disorders (DSM-5). Eligible participants typically report persistent sleep disturbances (e.g., difficulty falling asleep, frequent nighttime awakenings, early-morning awakening, or non-restorative sleep) lasting at least 3 months, occurring at least 3 nights per week, and causing significant daytime impairment (such as fatigue, mood disturbances, cognitive dysfunction, or reduced work/activity capacity). This age group (40-69 years) is characterized by a high prevalence of insomnia, often associated with physiological changes (e.g., declining sleep efficiency, altered circadian rhythms), chronic comorbidities (e.g., hypertension, diabetes, musculoskeletal disorders), psychological stress, or lifestyle factors (e.g., sedentary behavior, irreg
Trial design
Case-control
Prospective
Treatments tested in this trial
Tai Chi and Walking
Other intervention1. Frequency: Train three times a week on a fixed day (e.g., Monday, Wednesday, Friday) to avoid two consecutive days of no training and ensure continuity; 2. Duration: 40 minutes for the basic preparation phase, and 60 minutes for the advanced learning and integration phase (including warm-up, core training, and relaxation). 3. Attendance requirement: Participants must complete at least 19 training sessions (24 sessions over 8 weeks with an attendance rate of ≥80%). In case of absence due to special circumstances, they must complete supplementary training via online video (instructor-recorded action breakdowns) within one week, with the same duration as regular sessions.
Treatment groups
Trial outcomes
Primary outcomes
Pittsburgh Sleep Quality Index (PSQI)
The Pittsburgh Sleep Quality Index (PSQI) is a widely used self-report questionnaire designed to assess subjective sleep quality over a 1-month period. Developed by Buysse et al. in 1989, it consists of 19 individual items categorized into 7 components: subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleeping medication, and daytime dysfunction. Each component is scored on a 0-3 scale, with total scores ranging from 0 to 21. A total score ≥ 7 indicates poor sleep quality, while a score \< 7 reflects good sleep quality. The PSQI is recognized for its simplicity, reliability, and validity across diverse populations, including healthy individuals, patients with chronic diseases, and those with sleep disorders. It is extensively employed in clinical research, epidemiological studies, and clinical practice to evaluate sleep outcomes, particularly in fields such as medicine, psychology, public health, and complementary and altern
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: